Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label trial designed to assess the safety and efficacy of
ranolazine (Ranexa) in patients with pulmonary hypertension associated with left ventricular
diastolic dysfunction. All patients will receive active drug. The study includes a screening
period, 6 month treatment period and a follow up period. Eligible patients who provide
informed consent and who meet all inclusion/exclusion criteria will be enrolled in this
study.
There is neither proven therapy for patients with diastolic dysfunction-associated pulmonary
hypertension nor for patients with diastolic dysfunction alone. Ranolazine, an inhibitor of
cardiac repolarization (sodium channels), could represent a new and effective treatment of
this entity.